×
S&P 500   3,818.67 (-0.17%)
DOW   30,868.23 (-0.74%)
QQQ   285.44 (+1.17%)
AAPL   140.95 (+1.45%)
MSFT   261.78 (+0.85%)
META   166.84 (+4.26%)
GOOGL   2,256.96 (+3.78%)
AMZN   113.49 (+3.59%)
TSLA   692.96 (+1.64%)
NVDA   148.42 (+2.20%)
NIO   21.93 (+2.67%)
BABA   117.90 (+1.64%)
AMD   74.67 (+1.36%)
MU   56.41 (+5.14%)
CGC   2.67 (-4.98%)
T   21.06 (-1.17%)
GE   61.27 (-3.57%)
F   11.10 (-1.94%)
DIS   96.63 (+0.51%)
AMC   12.67 (-6.36%)
PFE   51.27 (-1.99%)
PYPL   74.16 (+3.87%)
NFLX   183.83 (+2.16%)
S&P 500   3,818.67 (-0.17%)
DOW   30,868.23 (-0.74%)
QQQ   285.44 (+1.17%)
AAPL   140.95 (+1.45%)
MSFT   261.78 (+0.85%)
META   166.84 (+4.26%)
GOOGL   2,256.96 (+3.78%)
AMZN   113.49 (+3.59%)
TSLA   692.96 (+1.64%)
NVDA   148.42 (+2.20%)
NIO   21.93 (+2.67%)
BABA   117.90 (+1.64%)
AMD   74.67 (+1.36%)
MU   56.41 (+5.14%)
CGC   2.67 (-4.98%)
T   21.06 (-1.17%)
GE   61.27 (-3.57%)
F   11.10 (-1.94%)
DIS   96.63 (+0.51%)
AMC   12.67 (-6.36%)
PFE   51.27 (-1.99%)
PYPL   74.16 (+3.87%)
NFLX   183.83 (+2.16%)
S&P 500   3,818.67 (-0.17%)
DOW   30,868.23 (-0.74%)
QQQ   285.44 (+1.17%)
AAPL   140.95 (+1.45%)
MSFT   261.78 (+0.85%)
META   166.84 (+4.26%)
GOOGL   2,256.96 (+3.78%)
AMZN   113.49 (+3.59%)
TSLA   692.96 (+1.64%)
NVDA   148.42 (+2.20%)
NIO   21.93 (+2.67%)
BABA   117.90 (+1.64%)
AMD   74.67 (+1.36%)
MU   56.41 (+5.14%)
CGC   2.67 (-4.98%)
T   21.06 (-1.17%)
GE   61.27 (-3.57%)
F   11.10 (-1.94%)
DIS   96.63 (+0.51%)
AMC   12.67 (-6.36%)
PFE   51.27 (-1.99%)
PYPL   74.16 (+3.87%)
NFLX   183.83 (+2.16%)
S&P 500   3,818.67 (-0.17%)
DOW   30,868.23 (-0.74%)
QQQ   285.44 (+1.17%)
AAPL   140.95 (+1.45%)
MSFT   261.78 (+0.85%)
META   166.84 (+4.26%)
GOOGL   2,256.96 (+3.78%)
AMZN   113.49 (+3.59%)
TSLA   692.96 (+1.64%)
NVDA   148.42 (+2.20%)
NIO   21.93 (+2.67%)
BABA   117.90 (+1.64%)
AMD   74.67 (+1.36%)
MU   56.41 (+5.14%)
CGC   2.67 (-4.98%)
T   21.06 (-1.17%)
GE   61.27 (-3.57%)
F   11.10 (-1.94%)
DIS   96.63 (+0.51%)
AMC   12.67 (-6.36%)
PFE   51.27 (-1.99%)
PYPL   74.16 (+3.87%)
NFLX   183.83 (+2.16%)
NASDAQ:AGIO

Agios Pharmaceuticals Stock Forecast, Price & News

$25.01
+1.65 (+7.06%)
(As of 07/5/2022 02:52 PM ET)
Add
Compare
Today's Range
$22.75
$25.10
50-Day Range
$17.06
$24.14
52-Week Range
$16.75
$58.61
Volume
22,333 shs
Average Volume
868,415 shs
Market Capitalization
$1.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.57

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
113.8% Upside
$50.57 Price Target
Short Interest
Bearish
12.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.09
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($7.02) to ($6.44) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.05 out of 5 stars

Medical Sector

310th out of 1,428 stocks

Pharmaceutical Preparations Industry

146th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Agios Pharmaceuticals logo

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AGIO Stock News Headlines

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Up 10.1%
7 Analysts Have This to Say About Agios Pharmaceuticals
Agios Announces Evolution of Research Organization
Agios: Approved Product, Upcoming Catalysts
Agios Pharma Tops Q1 EPS by 7c
Agios Pharmaceuticals Q1 2022 Earnings Preview
Agios to Participate in March Investor Conferences
What 5 Analyst Ratings Have To Say About Agios Pharmaceuticals
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
390
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
7/05/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$50.57
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+102.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57142857142857
Research Coverage
7 Analysts

Profitability

Net Income
$1.60 billion
Pretax Margin
-43,318.15%

Debt

Sales & Book Value

Annual Sales
$203.20 million
Book Value
$23.79 per share

Miscellaneous

Free Float
52,334,000
Market Cap
$1.37 billion
Optionable
Optionable
Beta
1.34














Agios Pharmaceuticals Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Agios Pharmaceuticals stock.
View analyst ratings for Agios Pharmaceuticals
or view top-rated stocks.

What is Agios Pharmaceuticals' stock price forecast for 2022?

7 Wall Street analysts have issued 12 month target prices for Agios Pharmaceuticals' stock. Their AGIO stock forecasts range from $16.00 to $96.00. On average, they predict Agios Pharmaceuticals' stock price to reach $50.57 in the next twelve months. This suggests a possible upside of 102.9% from the stock's current price.
View analysts' price targets for Agios Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Agios Pharmaceuticals' stock performed in 2022?

Agios Pharmaceuticals' stock was trading at $32.87 at the beginning of 2022. Since then, AGIO shares have decreased by 24.2% and is now trading at $24.93.
View the best growth stocks for 2022 here
.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Agios Pharmaceuticals
.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.85) by $0.11. The biopharmaceutical company had revenue of $0.83 million for the quarter, compared to the consensus estimate of $2.71 million. During the same quarter last year, the company earned ($1.31) EPS.
View Agios Pharmaceuticals' earnings history
.

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Dr. Jacqualyn A. Fouse Ph.D., CEO & Director (Age 61, Pay $1.32M)
  • Mr. Jonathan Biller J.D., CFO & Head of Corp. Affairs (Age 57, Pay $804.18k)
  • Dr. Bruce Car Ph.D., Exec. Officer (Age 60, Pay $776.12k)
  • Dr. Sarah Gheuens M.D., Ph.D., Chief Medical Officer (Age 42, Pay $1.57M)
  • Ms. Richa Poddar, Chief Commercial Officer (Age 40, Pay $624.08k)
  • Dr. Lewis Clayton Cantley Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 73)
  • Dr. Tak Wah Mak, Co-Founder & Member of Scientific Advisory Board (Age 76)
  • Dr. Craig B. Thompson, Co-Founder & Chairman of Scientific Advisory Board (Age 69)
  • Dr. Shin-San Su Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 66)
  • Mr. T. J. Washburn Jr., Principal Accounting Officer (Age 41)

What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals CEO Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among Agios Pharmaceuticals' employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $24.93.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.37 billion and generates $203.20 million in revenue each year. The biopharmaceutical company earns $1.60 billion in net income (profit) each year or ($6.45) on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

Agios Pharmaceuticals employs 390 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for Agios Pharmaceuticals is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.